Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akorn AKRXQ

Healthcare Drug Manufacturers - Major
Akorn Inc is a pharmaceutical company. It is engaged in the development, manufacturing, and marketing of generic and prescription pharmaceuticals. The firm has two segments namely Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals including sterile ophthalmics, injectables, and inhalants, and... see more

Recent & Breaking News (OTCPK:AKRXQ)

Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown

PR Newswire May 3, 2023

Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown

PR Newswire April 26, 2023

Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM

PR Newswire October 27, 2022

Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg

PR Newswire August 16, 2022

Akorn Provides First Quarter 2020 Results

GlobeNewswire May 11, 2020

Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600

PR Newswire April 27, 2020

Akorn Provides Update on Sale Process

PR Newswire April 1, 2020

Akorn Provides Fourth Quarter and Full Year 2019 Results

GlobeNewswire February 26, 2020

Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business

PR Newswire February 12, 2020

Akorn Announces Extension of Standstill Agreement

GlobeNewswire December 16, 2019

Akorn to Present at the Credit Suisse Healthcare Conference

GlobeNewswire November 5, 2019

Akorn Provides Preliminary Third Quarter 2019 Results

GlobeNewswire October 31, 2019

Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

GlobeNewswire October 14, 2019

Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call

GlobeNewswire October 14, 2019

Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%

GlobeNewswire August 26, 2019

Akorn Provides Preliminary Second Quarter 2019 Results

GlobeNewswire August 1, 2019

Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

GlobeNewswire July 11, 2019

Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%

GlobeNewswire June 28, 2019

Akorn Receives FDA Warning Letter

GlobeNewswire June 25, 2019

Akorn to Present at the Jefferies 2019 Global Healthcare Conference

GlobeNewswire May 30, 2019